Holen Sie sich die Stockscreener-App
10.38
20.00%
1.73
Handel nachbörslich:
10.22
-0.16
-1.54%
Schlusskurs vom Vortag:
$8.65
Offen:
$9.75
24-Stunden-Volumen:
1.93M
Relative Volume:
2.13
Marktkapitalisierung:
$525.47M
Einnahmen:
$89.04M
Nettoeinkommen (Verlust:
$-241.08M
KGV:
-1.9734
EPS:
-5.26
Netto-Cashflow:
$-194.72M
1W Leistung:
+12.34%
1M Leistung:
+0.68%
6M Leistung:
+4.95%
1J Leistung:
+63.72%
1-Tages-Spanne:
$9.725
$10.76
1-Wochen-Bereich:
$8.01
$10.76
52-Wochen-Spanne:
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Firmenname
Regenxbio Inc
Sektor
Branche
Telefon
240-552-8181
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
10.38 | 437.89M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.87 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.60 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
740.40 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.59 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
302.29 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-02-11 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-07 | Fortgesetzt | Raymond James | Outperform |
| 2024-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-06-07 | Eingeleitet | Goldman | Buy |
| 2024-03-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-08 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Fortgesetzt | Raymond James | Outperform |
| 2023-11-01 | Eingeleitet | Stifel | Buy |
| 2023-06-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Wedbush | Neutral |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-01-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-14 | Fortgesetzt | Raymond James | Outperform |
| 2019-06-05 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-25 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-11-08 | Bestätigt | BofA/Merrill | Neutral |
| 2018-08-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-23 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-05-09 | Bestätigt | Barclays | Overweight |
| 2018-04-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Eingeleitet | Mizuho | Neutral |
| 2017-11-09 | Fortgesetzt | Morgan Stanley | Overweight |
Alle ansehen
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
RGNX'S "Transformational" Promise Became a $2.40 Loss for Investors: Levi & Korsinsky, LLP - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - GlobeNewswire
Regenxbio at Leerink Global Healthcare Conference: Strategic Pipeline Advancements - Investing.com India
H.C. Wainwright cuts Regenxbio stock price target to $30 - Investing.com
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Regenxbio (RGNX): HC Wainwright Maintains Rating, Lowers Price T - GuruFocus
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - PR Newswire
REGENXBIO commends women leadership driving mission on International Womens Day - Traders Union
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - bdtonline.com
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript - Insider Monkey
Why REGENXBIO Inc. stock remains a top recommendation2026 Chart Watch & AI Based Trade Execution Alerts - Naître et grandir
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty - TipRanks
REGENXBIO Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm ... - bdtonline.com
REGENXBIO Inc. Sued for Securities Law Violations – - GlobeNewswire
Team powers gene therapy mission, REGENXBIO asserts - Traders Union
The Analyst Verdict: Regenxbio In The Eyes Of 8 Experts - Benzinga
Assessing Where Regenxbio Stands After FY25 Results (NASDAQ:RGNX) - Seeking Alpha
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire
Regenxbio: Q4 Earnings Snapshot - theheraldreview.com
Morgan Stanley Lowers Price Target for RGNX but Maintains Overwe - GuruFocus
REGENXBIO Q4 Earnings Call Highlights - MarketBeat
REGENXBIO outlines 2026 Duchenne, wet AMD, and diabetic retinopathy milestones while targeting pivotal data releases - MSN
RegenXBio Earnings Call Balances Gene Therapy Risks - TipRanks
REGENXBIO (RGNX) Eyes Key Developments in 2026 Amid Robust Pipel - GuruFocus
Regenxbio stock: Clear Street reiterates Buy on gene therapy data By Investing.com - Investing.com Canada
Regenxbio stock: Clear Street reiterates Buy on gene therapy data - Investing.com
REGENXBIO (NASDAQ:RGNX) Posts Earnings Results - MarketBeat
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure ... - Caledonian Record
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
Aug Catalysts: Is REGENXBIO Inc impacted by rising ratesQuarterly Profit Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Morgan Stanley cuts Regenxbio stock price target on model updates - Investing.com Nigeria
Morgan Stanley cuts Regenxbio stock price target on model updates By Investing.com - Investing.com Australia
Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience By GuruFocus - Investing.com Canada
Stifel cuts Regenxbio stock price target to $42 on gene therapy data - Investing.com UK
RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST - marketscreener.com
Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Regenxbio Inc earnings missed by $0.58, revenue fell short of estimates - Investing.com UK
Earnings call transcript: Regenxbio misses Q4 2025 expectations, stock dips - Investing.com
REGENXBIO Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Regenxbio: Fourth Quarter Financial Overview - Bitget
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
REGENXBIO ($RGNX) Releases Q4 2025 Earnings - Quiver Quantitative
Regenxbio Q4 revenue rises but loss widens as costs increase - TradingView
Regenxbio Earnings Report: Q4 Overview - Benzinga
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Yahoo Finance
Finanzdaten der Regenxbio Inc-Aktie (RGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):